KalVista Pharmaceuticals Files 8-K: Director Changes & Officer Compensation Updates
Ticker: KALV · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1348911
| Field | Detail |
|---|---|
| Company | Kalvista Pharmaceuticals, Inc. (KALV) |
| Form Type | 8-K |
| Filed Date | Oct 2, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $42,500, $10,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, disclosure
Related Tickers: KALV
TL;DR
KalVista 8-K: Director shuffle, exec pay changes, shareholder votes, and financial updates filed Oct 1, 2025.
AI Summary
On October 1, 2025, KalVista Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the departure of a director, the election of a new director, and updates to compensatory arrangements for certain officers. Additionally, the filing covers the submission of matters to a vote of security holders and includes a Regulation FD disclosure, along with financial statements and exhibits.
Why It Matters
This filing provides crucial updates on corporate governance and executive compensation, which can impact investor confidence and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing primarily concerns routine corporate governance and disclosure matters, not significant financial distress or operational setbacks.
Key Players & Entities
- KalVista Pharmaceuticals, Inc. (company) — Registrant
- October 1, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-36830 (identifier) — SEC File Number
FAQ
Who departed as a director of KalVista Pharmaceuticals, Inc.?
The filing indicates the departure of a director, but the specific name is not provided in the summary information.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 1, 2025.
What are the main topics covered in this 8-K filing?
The filing covers the departure of directors, election of directors, compensatory arrangements of officers, submission of matters to a vote of security holders, Regulation FD disclosure, and financial statements/exhibits.
What is the SEC file number for KalVista Pharmaceuticals, Inc.?
The SEC file number for KalVista Pharmaceuticals, Inc. is 001-36830.
What is the state of incorporation for KalVista Pharmaceuticals, Inc.?
KalVista Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 981 words · 4 min read · ~3 pages · Grade level 10.6 · Accepted 2025-10-02 07:15:32
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 Par Value Per Share KALV The Nasdaq
- $42,500 — n stock, and (ii) an annual retainer of $42,500 paid in cash. In addition, Ms. Sensenig
- $10,000 — In addition, Ms. Sensenig will receive $10,000 in committee fees per year for service
Filing Documents
- d945945d8k.htm (8-K) — 38KB
- d945945dex991.htm (EX-99.1) — 8KB
- 0001193125-25-227478.txt ( ) — 161KB
- kalv-20251001.xsd (EX-101.SCH) — 3KB
- kalv-20251001_lab.xml (EX-101.LAB) — 17KB
- kalv-20251001_pre.xml (EX-101.PRE) — 11KB
- d945945d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press release dated October 2, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALVISTA PHARMACEUTICALS, INC. Date: October 2, 2025 By: /s/ Benjamin L. Palleiko Benjamin L. Palleiko Chief Executive Officer